Okay, we are WAY behind. And unfortunately a bit out of order. Skipping ahead to January 2020 for this round of 37 papers. Will try to wrap up 2019 next. Thanks again to Nicola Gerbino, Rebecca Martinez, Cathleen Beliveau, and Irene Liu at www.csuhsf.org for keeping this alive! 1) Commentary on Hoots et al. (2019): TheRead More
PubMed Update August 2019
9 papers this month. Thanks again to Rebecca Martinez, Cathleen Beliveau, Nataliya Karashchuk, and Laila Esfandiari at the Center on Substance Use and Health (www.csuhsf.org) for collaborating to produce these summaries! 1) Supervised injectable opioid agonist therapy in a supported housing setting for the treatment of severe opioid use disorder. Brar R, Sutherland C, Nolan S.Read More
PubMed Update July 2019
Good month. 40 papers. I think the main takeaway here is the buprenorphine waiver required for U.S. providers to treat their patients with buprenorphine – it needs to go. It is an archaic and absurd construct essentially invented by the US Supreme Court a century ago when the court decided “addiction is not a disease”.Read More
PubMed Update May 2019
17 articles for May 2019. Lots on naloxone. June coming soon! Thanks again to Rebecca Martinez, Cathleen Beliveau, Nataliya Karashchuk, and Laila Esfandiari at the Center on Substance Use and Health (www.csuhsf.org) for collaborating to produce these summaries! __ 1) Opioid overdose history and awareness of naloxone in patients seeking outpatient detoxification. Bhardwaj SB, Cochran G,Read More
PubMed Update March 2019
43 new papers for March of 2019. 1) Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. Krieter P, Gyaw S, Crystal R, Skolnick P. J Pharmacol Exp Ther. 2019 Apr 2. pii: jpet.118.256115. doi: 10.1124/jpet.118.256115. [Epub ahead of print] Comments: Nalmefene has high affinity and >7h duration of effect. But not atRead More
PubMed Update January 2019
We start out 2019 with 42 new papers. The overarching theme is fentanyl – with some useful data really starting to emerge. Also several addressing surveillance-type issues, which is still badly needed and exciting work. We’ve also got the standard naloxone papers and a few weird drugs (e.g. tramadol and kratom). 1) Drugs Most Frequently InvolvedRead More